306 related articles for article (PubMed ID: 21529330)
1. Aldosterone, from (patho)physiology to treatment in cardiovascular and renal damage.
Waanders F; de Vries LV; van Goor H; Hillebrands JL; Laverman GD; Bakker SJ; Navis G
Curr Vasc Pharmacol; 2011 Sep; 9(5):594-605. PubMed ID: 21529330
[TBL] [Abstract][Full Text] [Related]
2. Have the renin-angiotensin-aldosterone system perturbations in cardiovascular disease been exhausted?
Mansur SJ; Hage FG; Oparil S
Curr Cardiol Rep; 2010 Nov; 12(6):450-63. PubMed ID: 20827517
[TBL] [Abstract][Full Text] [Related]
3. Effect of aldosterone and MR blockade on the brain and the kidney.
Stier CT; Rocha R; Chander PN
Heart Fail Rev; 2005 Jan; 10(1):53-62. PubMed ID: 15947892
[TBL] [Abstract][Full Text] [Related]
4. Fibroblast growth factor 23 and the antiproteinuric response to dietary sodium restriction during renin-angiotensin-aldosterone system blockade.
Humalda JK; Lambers Heerspink HJ; Kwakernaak AJ; Slagman MC; Waanders F; Vervloet MG; Ter Wee PM; Navis G; de Borst MH;
Am J Kidney Dis; 2015 Feb; 65(2):259-66. PubMed ID: 25278093
[TBL] [Abstract][Full Text] [Related]
5. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.
Remuzzi G; Perico N; Macia M; Ruggenenti P
Kidney Int Suppl; 2005 Dec; (99):S57-65. PubMed ID: 16336578
[TBL] [Abstract][Full Text] [Related]
6. Aldosterone blockade in CKD: emphasis on pharmacology.
Schwenk MH; Hirsch JS; Bomback AS
Adv Chronic Kidney Dis; 2015 Mar; 22(2):123-32. PubMed ID: 25704349
[TBL] [Abstract][Full Text] [Related]
7. The endothelin-aldosterone axis and cardiovascular diseases.
Rossi GP; Cavallin M; Nussdorfer GG; Pessina AC
J Cardiovasc Pharmacol; 2001 Nov; 38 Suppl 2():S49-52. PubMed ID: 11811378
[TBL] [Abstract][Full Text] [Related]
8. Combination therapy with aldosterone blockade and renin-angiotensin inhibitors confers organ protection.
Sato A; Saruta T; Funder JW
Hypertens Res; 2006 Apr; 29(4):211-6. PubMed ID: 16778327
[TBL] [Abstract][Full Text] [Related]
9. Mineralocorticoid receptor antagonist for renal protection.
Ma TK; Szeto CC
Ren Fail; 2012; 34(6):810-7. PubMed ID: 22463731
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of the renin-angiotensin-aldosterone system for cerebrorenal protection.
Lambers Heerspink HJ
Contrib Nephrol; 2013; 179():7-14. PubMed ID: 23652444
[TBL] [Abstract][Full Text] [Related]
11. Effect of MR blockade on collagen formation and cardiovascular disease with a specific emphasis on heart failure.
Zannad F; Radauceanu A
Heart Fail Rev; 2005 Jan; 10(1):71-8. PubMed ID: 15947894
[TBL] [Abstract][Full Text] [Related]
12. Combined blockade of renin-angiotensin-aldosterone system reduced all-cause but not cardiovascular mortality in dialysis patients: A mediation analysis and systematic review.
Li SM; He WB; Chen J; Cai QQ; Huang FF; Zhang K; Wang JF; Liu X; Huang H
Atherosclerosis; 2018 Feb; 269():35-41. PubMed ID: 29258005
[TBL] [Abstract][Full Text] [Related]
13. Aldosterone and parathyroid hormone interactions as mediators of metabolic and cardiovascular disease.
Tomaschitz A; Ritz E; Pieske B; Rus-Machan J; Kienreich K; Verheyen N; Gaksch M; Grübler M; Fahrleitner-Pammer A; Mrak P; Toplak H; Kraigher-Krainer E; März W; Pilz S
Metabolism; 2014 Jan; 63(1):20-31. PubMed ID: 24095631
[TBL] [Abstract][Full Text] [Related]
14. Hypertension: renin-angiotensin-aldosterone system alterations.
Te Riet L; van Esch JH; Roks AJ; van den Meiracker AH; Danser AH
Circ Res; 2015 Mar; 116(6):960-75. PubMed ID: 25767283
[TBL] [Abstract][Full Text] [Related]
15. Cardiorenal protection during chronic renin-angiotensin-aldosterone system suppression: evidences and caveats.
Ruiz-Hurtado G; Ruilope LM
Eur Heart J Cardiovasc Pharmacother; 2015 Apr; 1(2):126-31. PubMed ID: 27533982
[TBL] [Abstract][Full Text] [Related]
16. Triple pharmacological blockade of the renin-angiotensin-aldosterone system in nondiabetic CKD: an open-label crossover randomized controlled trial.
Tylicki L; Rutkowski P; Renke M; Larczyński W; Aleksandrowicz E; Lysiak-Szydlowska W; Rutkowski B
Am J Kidney Dis; 2008 Sep; 52(3):486-93. PubMed ID: 18423812
[TBL] [Abstract][Full Text] [Related]
17. Beneficial long-term effect of aldosterone antagonist added to a traditional blockade of the renin-angiotensin-aldosterone system among patients with obesity and proteinuria.
Morales E; Gutiérrez E; Caro J; Sevillano A; Rojas-Rivera J; Praga M
Nefrologia; 2015; 35(6):554-61. PubMed ID: 26519114
[TBL] [Abstract][Full Text] [Related]
18. The renin-angiotensin-aldosterone system as a target in coronary disease.
O'Keefe JH; Lurk JT; Kahatapitiya RC; Haskin JA
Curr Atheroscler Rep; 2003 Mar; 5(2):124-30. PubMed ID: 12573198
[TBL] [Abstract][Full Text] [Related]
19. Dual blockade of the renin-angiotensin-aldosterone system in cardiac and renal disease.
Slagman MC; Navis G; Laverman GD
Curr Opin Nephrol Hypertens; 2010 Mar; 19(2):140-52. PubMed ID: 20051849
[TBL] [Abstract][Full Text] [Related]
20. Review of aldosterone- and angiotensin II-induced target organ damage and prevention.
Struthers AD; MacDonald TM
Cardiovasc Res; 2004 Mar; 61(4):663-70. PubMed ID: 14985063
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
